56546-36-2

Usage

Uses

Used in Chemical Research:
(2-OXOPYRIDIN-1(2H)-YL)ACETIC ACID is used as a research compound for studying its chemical properties and potential interactions with other molecules, contributing to the advancement of organic chemistry.
Used in Organic Synthesis:
As a building block, (2-OXOPYRIDIN-1(2H)-YL)ACETIC ACID is used in the synthesis of a variety of organic compounds, facilitating the creation of new chemical entities with diverse applications.
Used as a Reagent in Organic Reactions:
(2-OXOPYRIDIN-1(2H)-YL)ACETIC ACID is employed as a reagent in multiple organic reactions, aiding in the transformation of starting materials into desired products, which is crucial for the development of new chemical processes and methodologies.
Used in Pharmaceutical Development:
(2-OXOPYRIDIN-1(2H)-YL)ACETIC ACID may be utilized as a starting material or intermediate in the development of pharmaceuticals, given its unique structure and properties that could be harnessed for therapeutic purposes.
Used in the Synthesis of Active Pharmaceutical Ingredients (APIs):
In the pharmaceutical industry, (2-OXOPYRIDIN-1(2H)-YL)ACETIC ACID is used as a key component in the synthesis of APIs, potentially leading to the discovery of new drugs with novel mechanisms of action.

InChI:InChI=1/C7H7NO3/c9-6-3-1-2-4-8(6)5-7(10)11/h1-4H,5H2,(H,10,11)

Upstream product

• 1628-89-3 2-methoxypyridine 
• 5199-50-8 methyl 2-iodoacetate 
• 126202-06-0 2-(2-imino-1,2-dihydropyridin-1-yl)acetic acid 
• 80056-43-5 (2-oxo-2H-pyridin-1-yl)-acetic acid ethyl ester 
• 142-08-5 2-Pyridone 
• 109-09-1 2-chloropyridine 
• 40864-08-2 2-benzyloxypyridine 
• 142-08-5 2-hydroxypyridin 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 22280-38-2 2-oxo-3-trifluoroacetyl-2,3-dihydro-oxazolo[3,2-a]pyridinylium betaine 
• 213550-26-6 N-{(R)-2-[Bis-(4-methoxy-phenyl)-phenyl-methoxy]-1-hydroxymethyl-ethyl}-2-(2-oxo-2H-pyridin-1-yl)-acetamide 
• 1222979-21-6 (2-oxo-2H-pyridin-1-yl)acetic acid 2-[2,5-dimethyl-1-(4-trifluoromethoxyphenyl)-1H-pyrrol-3-yl]-2-oxoethyl ester 
• 1586819-87-5 N-(2-benzoylphenyl)-2-(2-oxo-2H-pyridin-1-yl)acetamide 
• 1088201-27-7 N-(4-methoxyphenyl)-2-(2-oxopyridin-1(2H)-yl)acetamide 
• 22280-40-6 2-(2-oxopyridin-1(2H)-yl)-N-phenylacetamide 
• 106522-07-0 N-benzyl-2-(2-oxopyridin-1(2H)-yl)acetamide 

Relevant academic research and scientific papers

Route exploration and synthesis of the reported pyridone-based PDI inhibitor STK076545

The enzyme protein disulfide isomerase (PDI) is essential for the correct folding of proteins and the activation of certain cell surface receptors, and is a promising target for the treatment of cancer and thrombotic conditions. A previous high-throughput screen identified the commercial compound STK076545 as a promising PDI inhibitor. To confirm its activity and support further biological studies, a resynthesis was pursued of the reported β-keto-amide with an N-alkylated pyridone at the α-position. Numerous conventional approaches were complicated by undesired fragmentations or rearrangements. However, a successful 5-step synthetic route was achieved using an aldol reaction with an α-pyridone allyl ester as a key step. An X-ray crystal structure of the final compound confirmed that the reported structure of STK076545 was achieved, however its lack of PDI activity and inconsistent spectral data suggest that the commercial structure was misassigned.

Nitrogen heterocyclic ring group substituted amide derivative and application thereof

The invention discloses a nitrogen heterocyclic ring group substituted amide derivative and application thereof, particularly relates to a novel nitrogen heterocyclic ring group substituted amide derivative and a drug composition comprising the compound, and further relates to methods for preparing the compound and the drug composition, and application of the compound and the drug composition to preparation of drugs for treating diseases or symptoms, particularly overactive bladder, excited and mediated by beta 3-adrenergic receptors. The compound and the drug composition can be used for activating the beta 3-adrenergic receptors.

Development of novel amides as noncovalent inhibitors of immunoproteasomes

The development of immunoproteasome-selective inhibitors is a promising strategy for treating hematologic malignancies, autoimmune and inflammatory diseases. In this context, we report the design, synthesis, and biological evaluation of a new series of amide derivatives as immunoproteasome inhibitors. Notably, the designed compounds act as noncovalent inhibitors, which might be a promising therapeutic option because of the lack of drawbacks and side effects associated with irreversible inhibition. Among the synthesized compounds, we identified a panel of active inhibitors with Ki values in the low micromolar or sub-micromolar ranges toward the b5i and/or b1i subunits of immunoproteasomes. One of the active compounds was shown to be the most potent and selective inhibi-tor with a Ki value of 21 nm against the single b1i subunit. Docking studies allowed us to determine the mode of binding of the molecules in the catalytic site of immunoproteasome subunits.

HETEROCYCLIC COMPOUNDS WITH MICROBIOCIDAL PROPERTIES

The present disclosure relates to a compound of Formula I, wherein the substituents T, A, W, R2, n, Z, G, Z1 and J are as defined in the description.

Development of peptidomimetic boronates as proteasome inhibitors

Proteasome inhibition has emerged over the past decade as an effective therapeutic approach for the treatment of hematologic malignancies. It is a multicatalytic complex, whose proteolytic activity relies in three types of subunits: chymotrypsin-like (β5), trypsin-like (β2) and caspase-like (β1). Most important for the development of effective antitumor agents is the inhibition of the β5 subunits. In this context, the dipeptide boronate bortezomib (Velcade) represents the first proteasome inhibitor approved by the FDA and the lead compound in drug discovery. This paper describes the synthesis and biological evaluation of a series of conformationally constrained pseudopeptide boronates (1-3) structurally related to bortezomib. The synthesized compounds showed a promising inhibitory profile by blocking primarily the chymotrypsin-like activity of the proteasome with Ki values in submicromolar/micromolar range. These compounds also resulted quite selective since no significant inhibition was recorded in the test against bovine pancreatic α-chymotrypsin. The obtained results were rationalized by means of docking experiments based on a model of the crystal structure of bortezomib bound to the yeast 20S proteasome providing essential insights for further optimization of this class of inhibitors.

Value of zeolites in asymmetric induction during photocyclization of pyridones, cyclohexadienones and naphthalenones

Two strategies, namely chiral inductor and chiral auxiliary approaches, have been examined within zeolites with the aim of achieving asymmetric induction during the photocyclization of cyclohexadienone, naphthalenone and pyridone derivatives. Within zeoli

7-Acyl-3-(sulfaminoalkyl substituted tetrazolylthiomethyl)cephalosporins, antibacterial compositions containing them and methods of treating bacterial infections with them

The compounds of this invention are cephalosporins having various acyl substituents at the 7-position and a sulfaminoalkyl substituted tetrazolylthiomethyl group at the 3-position of the cephem nucleus and intermediates for the preparation thereof. The 7-acylated cephalosporin compounds have antibacterial activity.

7β-Acylamino-3-(phosphonoalkyl and esterified phosphonoalkyl substituted tetrazolylthiomethyl)cephalosporins

The compounds of this invention are cephalosporins having various acylamino substituents at the 7-position and a phosphonoalkyl or esterified phosphonoalkyl substituted tetrazolylthiomethyl group at the 3-position of the cephem nucleus and intermediates for the preparation thereof. The 7-acylated compounds have antibacterial activity.